Scientific Advisors
Roger B. Cohen, MD
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Dr. Cohen is a medical oncologist with expertise in the development and use of novel cancer treatments for a variety of cancers. Dr. Cohen specializes in patients with a variety of cancers, including lung, head and neck, breast, and thyroid cancer as well as cancers of unknown primary site. Dr. Cohen's research focuses on clinical trials of new anticancer treatments, including medicines and combinations of medicines being given to patients for the first time. In the course of this research, Dr. Cohen is working on new treatment options that he hopes will will prove effective and eventually become available to patients with cancer everywhere
Manuel Hidalgo, MD/PhD
Johns Hopkins Cancer Center
Baltimore, Maryland
Dr. Manuel Hidalgo, M.D., Ph.D., is the Associate Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine and Director of the Centro Integral Oncologia "Clara Campal" in Madrid, Spain. He is considered a leading researcher in the field of targeted therapies for the treatment of cancer in patients with solid tumors. His research interest focuses on the development of novel anticancer agents for patients with gastrointestinal cancer by measuring target receptor and molecular anomalies, as well as analyzing biological activity in the tumor and normal tissues of patients treated with specific therapies.
Dr. Hidalgo has published over 140 papers in leading cancer journals as well as numerous chapters in major textbooks. He has received numerous awards including an AACR Young Investigator Award, an NCI-EORTC fellowship and an ASCO Career Development Award. He has served on the editorial board of the Journal of Clinical Oncology and Clinical Cancer Research and is a Senior Editor for Molecular Cancer Therapeutics. Dr. Hidalgo has chaired the AACR and ASCO Program Committee in developmental therapeutics on numerous occasions and is frequently invited to speak at major national and international meetings. He chairs the Pancreatic Cancer Research Team, a nonprofit organization focused on clinical trials in pancreatic cancer and is also a member of the NCI Developmental Therapeutics Study Section.
Gordon Mills, MD/PhD
MD Anderson Cancer Center
Houston, Texas
Dr. Mills was recruited to The University of Texas MD Anderson Cancer Center, where he holds the rank of professor with joint appointments in Systems Biology, Breast Medical Oncology and Immunology; serves as chairman of the Department of Systems Biology; head of the section of Molecular Therapeutics and holds the Ann Rife Cox Chair in Gynecology. Dr. Mills is co-Director of the Kleberg Center for Molecular Markers and director for the Gita and Ali Saberioon Molecular Markers building.
With more than 300 publications, Dr. Mills has authored papers in such prestigious journals as Nature, Cell, Oncogene, Nature Genetics, Nature Medicine, Nature Cell Biology, Nature Cancer Reviews, Cancer Research, Proceedings of the National Academy of Sciences and Clinical Cancer Research.
Dr. Mills is the holder of more than 20 patents related to novel technologies and molecular markers. He was a co founder of an early diagnostics company. He currently sits on the scientific advisory boards of multiple different companies and venture capital groups. Based on his expertise in technology development, he is the head of the MD Anderson Cancer Center Technology Review Committee.
Ed Sausville, MD/PhD
University of Maryland Cancer Center
Baltimore, Maryland
Dr. Sausville is a Medical Oncologist and Pharmacologist who until 2004 was Associate Director of the National Cancer Institute's Division of Cancer Treatment and Diagnosis for the Developmental Therapeutics Program. This Program directs the NCI's preclinical anti-cancer drug development portfolio, from screening studies through formulation, manufacture, and safety testing for agents to enter clinical trial sponsored by NCI. As the Associate Director of Clinical Research at the University of Maryland, Dr. Sausville's research interest are directed at early phase clinical trials of new drugs for cancer treatment. His works entails new drug development and bringing new medicines and therapies out of the laboratory to patients’ bedsides.
One of the new drugs Dr. Sausville was instrumental in bringing to clinical study, in collaboration with Millennium Pharmaceuticals, was Velcade, the first of a new class of medicines called proteasome inhibitors that was approved last year by the U.S. Food and Drug Administration for treatment of multiple myeloma, a bone marrow cancer.
Michael Shattock, PhD
King's College of Medicine, St. Thomas Hospital, London, England
Professor Shattock is Professor of Cellular Cardiology and head of Cardiac Physiology Research Group at King’s College London. His research addresses how the expression, structure, activity and location of key ion translocating proteins may influence the response of the heart to ischemia, hypertophy and heart failure. Current research focuses on T-type Ca channels in cardiovascular disease and cell proliferation. He has authored over 230 papers or abstracts on cellular cardiology.
Professor Shattock is a Fellow of the American Heart Association (FAHA) and a Fellow of the European Society of Cardiology (FESC) He is on the Editorial Board and reviewing panel of numerous cardiology and physiology journals. He is, or has been, on the advisory board for a number of major pharmaceutical companies including Hoffman La Roche, Servier and Boehringer-Ingelheim and has advised the Medicines and Healthcare Products Regulatory Agency (MHRA), Wellcome Trust and MRC. He is currently serving on the Project Grants Committee of the British Heart Foundation.